Cost-Effectiveness of Intravenous Thrombolysis With Alteplase Within a 3-Hour Window After Acute Ischemic Stroke
- 1 January 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 38 (1) , 85-89
Abstract
Background and Purpose— The aim of this study was to assess the costs and cost-effectiveness of intravenous thrombolysis treatment with alteplase (Actilyse) of acute ischemic stroke with 24-hour in-house neurology coverage and use of magnetic resonance imaging. Methods— A health economic model was designed to calculate the marginal cost-effectiveness ratios for time spans of 1, 2, 3 and 30 years. Effect data were extracted from a meta-analysis of six large-scale randomized and placebo-controlled studies of thrombolytic therapy with alteplase. Cost data were extracted from thrombolysis treatment at Aarhus Hospital, Denmark, and from previously published literature. Results— The calculated cost-effectiveness ratio after the first year was $55 591 US per quality-adjusted life-year (base case). After the second year, computation of the cost-effectiveness ratio showed that thrombolysis was cost-effective. The long-term computations (30 years) showed that thrombolysis was a dominant strategy compared with conservative treatment given the model premises. Conclusions— A high-quality thrombolysis treatment with 24-hour in-house neurology coverage and magnetic resonance imaging might not be cost-effective in the short term compared with conservative treatment. In the long term, there are potentially large-scale health economic cost savings.Keywords
This publication has 15 references indexed in Scilit:
- MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort studyThe Lancet Neurology, 2006
- Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United StatesStroke, 2005
- Cost-Effectiveness Analysis of Thrombolytic Treatment for StrokeCerebrovascular Diseases, 2005
- Cost-Effectiveness of Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke Assessed by a Model Based on UK NHS CostsStroke, 2004
- Trial Application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to Assist Priority Setting in StrokeStroke, 2004
- Willingness to pay for a QALYHealth Economics, 2003
- Development of a Decision-Analytic Model of Stroke Care in the United States and EuropeValue in Health, 2002
- Cost-Utility Analysis of Tissue Plasminogen Activator Therapy for Acute Ischaemic StrokePharmacoEconomics, 2001
- Cost-effectiveness of tissue plasminogen activator for acute ischemic strokeNeurology, 1998
- An Introduction to Markov Modelling for Economic EvaluationPharmacoEconomics, 1998